The automated cell counter market has seen considerable growth due to a variety of factors.
• The automated cell counter market has seen steady growth in recent years. It is expected to rise from $5.42 billion in 2024 to $5.79 billion in 2025, reflecting a compound annual growth rate (CAGR) of 6.9%.
Growth is driven by greater awareness, advancements in diagnostic techniques, environmental factors, antifungal resistance, and growing immune-compromised populations.
The automated cell counter market is expected to maintain its strong growth trajectory in upcoming years.
• The automated cell counter market is forecast to see strong growth, reaching $7.48 billion by 2029, with a CAGR of 6.6%.
The expansion is attributed to regulatory support, healthcare spending, infectious disease outbreaks, and advancements in precision medicine. Trends include the development of biopharmaceuticals, increased research activities, remote monitoring, and point-of-care testing.
The rising adoption of personalized medicine is expected to boost the automated cell counter market. Personalized medicine involves tailoring treatments to each patient's unique genetic and health characteristics. Automated cell counters help analyze cell populations specific to each patient’s needs, aiding in treatment customization. According to the Personalized Medicine Coalition, the FDA approved 16 new personalized treatments for rare diseases in 2024, up from 6 in 2022. Therefore, the growing adoption of personalized medicine is driving the automated cell counter market.
The automated cell counter market covered in this report is segmented –
1) By Product: Consumable Accessories, Instruments
2) By Application: Blood Analysis, Urine Analysis, Microbial Cell Count, Cell Line Viability, Other Applications
3) By End User: Pharmaceuticals And Biotechnology Companies, Hospitals, Diagnostics Laboratories, Research Institutes, Other End-Users
Subsegments:
1) By Consumable Accessories: Cell Counting Reagents, Cell Counting Slides, Sample Tubes
2) By Instruments: Hemocytometers, Flow Cytometers, Automated Cell Counters (Optical Or Impedance-Based)
Companies in the automated cell counter market are incorporating AI and machine learning, such as AI-automated cell culture systems, to optimize and automate cell growth and scalability in biological research and biomanufacturing. These systems autonomously monitor and manage cell cultures in laboratory settings. For example, in October 2023, Molecular Devices LLC, a US-based analytical systems supplier, introduced the CellXpress.ai system. This end-to-end solution automates feeding and passaging schedules with an integrated incubator, liquid handler, and imager, powered by machine learning to streamline complex cell culture processes.
Major companies operating in the automated cell counter market are:
• Thermo Fisher Scientific Inc.
• Abbott Laboratories
• F.Hoffmann-La Roche Ltd.
• Danaher Corporation
• Merck KGaA
• BD Biosciences
• GE HealthCare Technologies Inc.
• Corning Incorporated
• Agilent Technologies Inc.
• Olympus Corporation
• Nikon Corporation
• PerkinElmer Inc.
• Sysmex Corporation
• Bio-Rad laboratories Inc.
• HORIBA Ltd.
• Eppendorf
• Tecan Group
• Miltenyi Biotec
• Luminex Corporation
• Molecular Devices LLC
• Chemometec A/S
• NanoEnTek Inc.
• Sony Biotechnology Inc.
• Countstar Inc.
• Aligned Genetics Inc.
North America was the largest region in the automated cell counter market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the automated cell counter market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.